Study shows importance of targeted antibody treatment for patients with wet macular degeneration

Wet age-related macular degeneration is one of the leading causes of blindness in the U.S. Breakthrough treatments come with a steep price tag and treatment burden for the patient, but a new study suggests their benefits to patient health and society top billions of dollars, or more, if adherence could be improved.

Full Story →